Nektar Therapeutics Inc $ 17.27 -0.5 (-2.81%)
On watch
Volume:
4,903,607
Avg Vol (1m):
3,977,558
Market Cap $:
3.03 Bil
Enterprise Value $:
1.86 Bil
P/E (TTM):
0.00
P/B:
1.94
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $17.27 | ||
Manual of Stocks™ Web
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 4.38 | ||
| Equity-to-Asset | 0.74 | ||
| Debt-to-Equity | 0.22 | ||
| Debt-to-EBITDA | -0.94 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 2.55 | ||
| Beneish M-Score | 4.32 | ||
| WACC vs ROIC | |||
Profitability | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -361.46 | ||
| Net Margin % | -354.9 | ||
| ROE % | -24.7 | ||
| ROA % | -19.25 | ||
| ROC (Joel Greenblatt) % | -423.08 | ||
| 3-Year Revenue Growth Rate | 56.1 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.94 | ||
| PS Ratio | 25.55 | ||
| EV-to-EBIT | -4.86 | ||
| EV-to-EBITDA | -5.02 | ||
| EV-to-Revenue | 15.6 | ||
| Current Ratio | 14.09 | ||
| Quick Ratio | 13.97 | ||
| Days Inventory | 197.84 | ||
| Days Sales Outstanding | 114.28 | ||
| Days Payable | 150.26 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.04 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.07 | ||
| Price-to-Median-PS-Value | 2.58 | ||
| Earnings Yield (Greenblatt) % | -20.58 |